Skip to main content
Terug
ZTS logo

Zoetis Inc.

Datakwaliteit: 100%
ZTS
NYSE Healthcare Drug Manufacturers - Specialty & Generic
€ 115,93
▲ € 0,70 (0,61%)
Marktkapitalisatie: 51,09B
Dagbereik
€ 113,31 € 117,11
52-Weeksbereik
€ 113,31 € 172,23
Volume
4.557.901
50D / 200D Gem.
€ 124,41 / € 138,35
Vorige Slotkoers
€ 115,23

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 19,1 0,3
P/B 15,3 2,9
ROE % 66,0 3,7
Net Margin % 28,2 3,8
Rev Growth 5Y % 5,0 10,0
D/E 2,9 0,2

Koersdoel Analisten

Hold
€ 143,86 +24.1%
Low: € 135,00 High: € 160,00
Forward K/W
16,4
Forward WPA
€ 7,01
WPA Groei (sch.)
+0,0%
Omzet Sch.
9,9 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 9,27
€ 9,10 – € 9,46
12 B 1
FY2029 € 8,69
€ 8,54 – € 8,88
11 B 1
FY2028 € 8,16
€ 7,75 – € 8,40
11 B 5

Belangrijkste Punten

Revenue grew 5,04% annually over 5 years — modest growth
ROE of 65,99% indicates high profitability
Net margin of 28,23% shows strong profitability
Debt/Equity of 2,85 — high leverage
Generating 2,28B in free cash flow
Cash machine — converts 85,41% of earnings into free cash flow

Groei

Revenue Growth (5Y)
5,04%
Revenue (1Y)2,28%
Earnings (1Y)7,52%
FCF Growth (3Y)18,68%

Kwaliteit

Return on Equity
65,99%
ROIC21,04%
Net Margin28,23%
Op. Margin38,00%

Veiligheid

Debt / Equity
2,85
Current Ratio3,03
Interest Coverage14,80

Waardering

P/E Ratio
19,11
P/B Ratio15,34
EV/EBITDA16,20
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2,28% Revenue Growth (3Y) 5,26%
Earnings Growth (1Y) 7,52% Earnings Growth (3Y) 6,79%
Revenue Growth (5Y) 5,04% Earnings Growth (5Y) 7,03%
Profitability
Revenue (TTM) 9,47B Net Income (TTM) 2,67B
ROE 65,99% ROA 17,28%
Gross Margin 70,49% Operating Margin 38,00%
Net Margin 28,23% Free Cash Flow (TTM) 2,28B
ROIC 21,04% FCF Growth (3Y) 18,68%
Safety
Debt / Equity 2,85 Current Ratio 3,03
Interest Coverage 14,80 Dividend Yield 0,02%
Valuation
P/E Ratio 19,11 P/B Ratio 15,34
P/S Ratio 5,40 PEG Ratio 2,04
EV/EBITDA 16,20 Dividend Yield 0,02%
Market Cap 51,09B Enterprise Value 58,27B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9,47B 9,26B 8,54B 8,08B 7,78B
Net Income 2,67B 2,49B 2,34B 2,11B 2,04B
EPS (Diluted) 6,02 5,47 5,07 4,49 4,27
Gross Profit 6,67B 6,40B 5,83B 5,48B 5,31B
Operating Income 3,60B 3,39B 3,07B 2,93B 2,80B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15,47B 14,24B 14,29B 14,93B 13,90B
Total Liabilities 12,14B 9,47B 9,30B 10,52B 9,36B
Shareholders' Equity 3,33B 4,77B 5,00B 4,41B 4,54B
Total Debt 9,49B 6,74B 6,76B 8,09B 6,74B
Cash & Equivalents 2,31B 1,99B 2,04B 3,58B 3,48B
Current Assets 6,77B 5,99B 6,34B 7,51B 6,93B
Current Liabilities 2,24B 3,41B 1,89B 3,17B 1,80B